Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.34 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CCL2 | P13500 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19804291 | 0.94 | POLB (0.42) | POLBAPEX1HTTTDP1MTNR1A | |
| SCHEMBL19804641 | 0.89 | POLB (0.37) | POLBAPEX1HTTTDP1MTNR1A | |
| SCHEMBL19796355 | 0.88 | POLB (0.36) | POLBAPEX1HTTTDP1MTNR1A | |
| SCHEMBL19804296 | 0.88 | POLB (0.39) | POLBAPEX1HTTTDP1MTNR1A | |
| SCHEMBL19804269 | 0.85 | CA1 (0.34) | POLBAPEX1HTTTDP1CA1 | |
| SCHEMBL19804103 | 0.84 | CA1 (0.35) | POLBAPEX1HTTTDP1CA1 | |
| SCHEMBL19796814 | 0.83 | CNR2 (0.35) | POLBAPEX1HTTTDP1MTNR1A | |
| SCHEMBL19624417 | 0.83 | POLB (0.39) | POLBAPEX1HTTTDP1HRH3 | |
| SCHEMBL19796358 | 0.82 | POLB (0.40) | POLBAPEX1HTTTDP1MTNR1A | |
| SCHEMBL19624604 | 0.82 | FFAR4 (0.35) | POLBAPEX1HTTTDP1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, C1S, AP3D1 | POLB 3105/4885APEX1 1385/4885HTT 4544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.